TGA / PMDA / NMPA · Asia-Pacific
erythropoietin — TGA / PMDA / NMPA regulatory status
erythropoietin regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Structured fields
- 4
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 12 published clinical programs and 5 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| CVAY736O12301 | Phase 3 | Novartis India | 2024-510635-21-00 |
| ERYTHROPOIETIN , Elritercept | Phase 3 | Takeda | 2025-523544-12-00 |
| Erythropoietin | Phase 3 | First People's Hospital | NCT03110341 |
| recombinant human erythropoietin | Phase 3 | First People's Hospital | NCT04910594 |
| Erythropoietin | Phase 2 | Chinese Academy of | NCT03914690 |
| recombinant human erythropoietin | Phase 2 | Chinese Academy of | NCT00808704 |
| recombinant human erythropoietin (rhEpo) | Phase 2 | Chinese Academy of | NCT00910234 |
| Recombinant erythropoietin stimulating protein | Phase 1 | Sunshine Guojian Pharmaceutical | NCT02356419 |
| YB-1113 | Phase 1 | BRIGHT MINDS BIOSCIENCES | NCT05494723 |
| recombinant human erythropoietin | Approved | Chinese Academy of | NCT02036073 |
| A2023519 | Unknown | First People's Hospital | NCT06012760 |
| Sucrose Iron，subcutaneous recombinant human erythropoietin，intravenous vitamin C | Unknown | First People's Hospital | NCT06968936 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 11197812 | Cosmetic formulations for topical applications containing erythropoietin-derived molecules | US |
| 10912791 | Compositions comprising antisense-encoded erythropoietin receptor and use thereof | US |
| 10456346 | Cosmetic formulations for topical applications containing erythropoietin-derived molecules | US |
| 10233452 | Compositions and methods for increasing erythropoietin (EPO) production | US |
| 7300915 | Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain | US |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of erythropoietin?
erythropoietin currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get erythropoietin regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to erythropoietin?
This spoke lists 12 published programs associated with erythropoietin in our pipeline index.